Value through Innovation23 October 2014
06 June 2013

Boehringer Ingelheim pioneers biopharmaceuticals move to China

•    First international company  using cell culture technology to produce
     biopharmaceuticals in China

•    Investment of over 35 million Euro

•    Up to 65 new jobs

Ingelheim, Germany, and Shanghai, China, 6 June 2013 - Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers. It will become the first facility established by a leading international biopharmaceuticals manufacturer in China utilizing mammalian cell culture technology.

The facility set up will include technical process development and cGMP manufacturing which will be ready for operations early 2016. Boehringer Ingelheim plans an investment of over 35 million EUR. The project will create up to 65 job opportunities with high qualification standards.

“Our partnership with ZJ Base Company is an important step in our global China strategy as it opens a further opportunity for Boehringer Ingelheim to participate in the growing demand for high quality biopharmaceuticals in China”, stated Christian Boehringer, Chairman of the Shareholders Committee.”Shanghai is our ideal partner with its advantages in investment environment, service system and talent resources.”

Lanzhong Wang, General Manager of the ZJ Base Company commented: “We are very pleased to start the partnership with a leading biopharmaceuticals company like Boehringer Ingelheim. Through the cooperation, we hope to bring here the know-how, technology and experience, all up to international standards. With a number of innovative medicines being developed by a cluster of middle to small-sized innovative companies in Zhangjiang, plus the government support, we plan to initiate the CMO manufacturing framework at this plant on a trial basis. This will provide an effective platform for middle and small-sized companies to industrialize their innovations. Thus, it will greatly prompt the development of China’s biopharmaceuticals manufacturing industry.”

Hubertus von Baumbach, member of the Board of Managing Directors, in charge of Finance, commented: “Since 1994 Boehringer Ingelheim is present in China and has established significant research, development, manufacturing and marketing activities. With our investments in these innovation-driven areas we strive to meet the needs of our customers. The move to invest in biopharmaceuticals is in line with China’s overall growth plan for the next five years. Biopharmaceuticals, together with prescription medicines, consumer health care, animal health and manufacturing, will form the five pillars driving our business in China.”

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. In 2012, Boehringer Ingelheim achieved net sales of about 14.6 billion Euro.

Boehringer Ingelheim Biopharma Contract Manufacturing is now represented by its new brand Boehringer Ingelheim BioXcellence™. As a leading biopharmaceutical contract manufacturer with more than 35 years of experience – the company has brought 22 biopharmaceutical products to market. Boehringer Ingelheim BioXcellence™ offers tailor-made contract development and manufacturing services to the biopharmaceutical industry, providing the entire production technology chain from DNA to fill and finish under one roof at its facilities in Biberach (Germany), Vienna (Austria) and Fremont (USA).
Boehringer Ingelheim BioXcellence™ can secure product supply throughout the entire product lifecycle—transferring customer projects at any stage, delivering to almost any scale and thereby makes outsourcing easy.

Contact:
May Yin
Communications
Boehringer Ingelheim China
200040 Shanghai
Phone: +86 (21) 52880000-5118
May.Yin@boehringer-ingelheim.com

More information:
www.bioxcellence.com
bioxcellence@boehringer-ingelheim.com
www.bioxcellence.cn

Media contact

  • Heidrun Thoma
    Boehringer Ingelheim

    Media & PR
    Heidrun Thoma
    Binger Strasse 173
    55216 Ingelheim am Rhein
    GERMANY

Media contact

  • Heidrun Thoma
    Boehringer Ingelheim

    Media & PR
    Heidrun Thoma
    Binger Strasse 173
    55216 Ingelheim am Rhein
    GERMANY